Events Partner Content Multi-Functional Cell Therapies Summit Development with Next-Generation Cell Therapies
News ASCO 25: J&J combo pill may see wider use in prostate cancer AMPLITUDE study of J&J's Akeega could extend the use of PARP inhibitors to hormone-responsive prostate cancer.
Market Access Sponsored Bridging research and clinical guidelines – interactive stra... Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential.
